Skip to main content
. 2015 May 29;6(21):18374–18388. doi: 10.18632/oncotarget.4073

Table 4a. Univariate and multivariate analysis with OS.

Variates Univariate analysis (OS) Multivariate analysis (OS)
HR 95% CI P value HR 95% CI P value
ENI 2.484 1.496–4.126 0.0004 2.988 1.396–6.399 0.0048
LDH 2.746 1.661–4.541 < 0.0001 1.502 0.777–2.903 0.2262
Stage 1.558 0.950–2.553 0.0787 0.674 0.325–1.399 0.2900
IPI 2.801 1.714–4.576 < 0.0001 0.809 0.343–1.908 0.6279
ECOG PS ≥ 2 2.552 1.486–4.383 0.0007 1.603 0.833–3.085 0.1580
MYC+ 5.515 3.339–9.108 < 0.0001 3.127 1.649–5.929 0.0005
BCL2+ 2.086 1.243–3.500 0.0054 0.934 0.465–1.875 0.8471
BCL6+ 0.665 0.415–1.066 0.0905 0.792 0.434–1.443 0.4458
Non-GCB 0.640 0.387–1.059 0.0825 0.710 0.335–1.502 0.3705
MYC-R+ 4.715 2.873–7.739 < 0.0001 7.527 2.358–24.031 0.0007
DHL 1.724 1.116–2.563 0.0070 1.595 1.005–2.534 0.0478
MYC CNA+ 5.344 2.790–10.234 < 0.0001 3.058 1.227–7.620 0.0164
BCL2 CNA+ 3.808 2.373–6.111 < 0.0001 2.619 1.417–4.840 0.0002
MC+BC+ 3.504 2.460–4.991 < 0.0001 2.414 1.510–3.860 0.0021

Abbreviations: OS: overall survival; HR: hazard; ENI: extranodal involvement; LDH: serum lactate dehydrogenase; IPI: International Prognostic Index; ECOG PS: performance status of Eastern Cooperative Oncology Group; +: positive; GCB: germinal-center B-cell; R: rearrangement; DHL: double hit lymphoma; CNA: copy number aberration; MC+BC+: double CNA of MYC and BCL2.